Publication:
Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer

No Thumbnail Available

Date

2022-01-29

Journal Title

Journal ISSN

Volume Title

Publisher

Springer Science and Business Media LLC
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Yi, Yang, Yanqiang Li, Chao Li, Longxiang Wu, Dongyu Zhao, Fuxi Li, Ladan Fazli et al. "Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer." Oncogene 41, no. 11 (2022): 1610-1621. DOI: 10.1038/s41388-022-02208-x

Research Data

Abstract

Cell division cycle associated 8 (CDCA8) is a component of chromosomal passenger complex (CPC) that participates in mitotic regulation. Although cancer-related CDCA8 hyperactivation has been widely observed, its molecular mechanism remains elusive. Here, we report that CDCA8 overexpression maintains tumorigenicity and is associated with poor clinical outcome in patients with prostate cancer (PCa). Notably, enhancer of zeste homologue 2 (EZH2) is identified to be responsible for CDCA8 activation in PCa. Genome-wide assays revealed that EZH2-induced H3K27 trimethylation represses let-7b expression and thus protects the let-7b-targeting CDCA8 transcripts. More importantly, EZH2 facilitates the self-activation of E2F1 by recruiting E2F1 to its own promoter region in a methylation-independent manner. The high level of E2F1 further promotes transcription of CDCA8 along with the other CPC subunits. Taken together, our study suggests that EZH2-mediated cell cycle regulation in PCa relies on both its methyltransferase and non-methyltransferase activities.

Description

Other Available Sources

Keywords

Cancer Research, Genetics, Molecular Biology

Terms of Use

Metadata Only

Endorsement

Review

Supplemented By

Referenced By

Related Stories